ESOPHAGOGASTRIC JUNCTION ADENOCARCINOMA
Clinical trials for ESOPHAGOGASTRIC JUNCTION ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new ESOPHAGOGASTRIC JUNCTION ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for ESOPHAGOGASTRIC JUNCTION ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New triple therapy shows promise in shrinking advanced stomach tumors before surgery
Disease control Recruiting nowThis study tests whether adding an immunotherapy drug (anti-PD-1) and an immune booster (thymalfasin) to standard chemotherapy (SOX) before surgery can help shrink stage III stomach or gastroesophageal junction cancer. About 30 adults aged 18-75 with HER2-negative cancer will rec…
Matched conditions: ESOPHAGOGASTRIC JUNCTION ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Zekuan Xu • Aim: Disease control
Last updated May 26, 2026 07:59 UTC
-
New combo therapy before surgery aims to boost stomach cancer outcomes
Disease control Recruiting nowThis early-phase trial tests a new combination of the immunotherapy drug tislelizumab plus standard chemotherapy (FLOT) given before surgery for patients with resectable stomach, esophageal, or gastroesophageal junction cancer. The goal is to see if this approach is safe and effe…
Matched conditions: ESOPHAGOGASTRIC JUNCTION ADENOCARCINOMA
Phase: PHASE1 • Sponsor: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest • Aim: Disease control
Last updated May 26, 2026 07:56 UTC
-
New combo therapy aims to keep stomach cancer from coming back after surgery
Disease control Recruiting nowThis study tests whether adding the drug sintilimab to standard chemotherapy after surgery can help prevent stage III stomach or GEJ cancer from returning. About 70 adults who have had their tumor removed will receive the combination for up to 16 cycles. The main goal is to see h…
Matched conditions: ESOPHAGOGASTRIC JUNCTION ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Disease control
Last updated May 26, 2026 07:52 UTC